Shilpa Medicare lunches pemetrexed injection in India under the brand name VRTU

Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India

Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries

The company has secured 506 marketing approvals for its oncology products across 76 countries.

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth

USFDA accepts biologics license application for GC Biopharma's GC5107B

Mandaviya chairs 7th meeting of Central Institute Body of AIIMS and Chintan Shivir at NIHFW, Delhi

Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference

NATCO files generic Erdafitinib Tablets in USA

Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023